When gastrointestinal stromal tumour (GIST), the most common form of sarcoma, was first
recognized as a distinct pathological entity in the 1990s, patients with advanced-stage …

Mesenchymal gastrointestinal cancers are represented by the gastrointestinal stromal
tumors (GISTs) which occur throughout the whole gastrointestinal tract, and affect human …

Over the past three to four decades, the molecular pathogenesis of gastrointestinal stromal
tumors (GISTs) has been elucidated in great detail. In this review, we discuss the biological …

Gastrointestinal stromal tumors (GISTs) are rare, mesenchymal tumors of the gastrointestinal
tract, characterized by either KIT or PDGFRA mutation in about 85% of cases. KIT/PDGFRA …

Objective: To determine the prognostic significance of inflammatory response-associated
genes in acute myeloid leukemia (AML). Methods: Transcriptomic profiles and related …

There is growing interest in the effect of innate immune silencing in “cold” tumors, which
always fail in the immune checkpoint blockade monotherapy using PD-L1 monoclonal …

Purpose: To create an in vivo model of PDGFRA D842V-mutant gastrointestinal stromal
tumor (GIST) and identify the mechanism of tumor persistence following avapritinib therapy …

Gastrointestinal stromal tumor (GIST), although rare, with an incidence of approximately 7 to
19 cases per million annually around the world, is the most common sarcoma of the …

Gastrointestinal stromal tumor (GIST) is the most common human sarcoma and is typically
driven by a single mutation in the Kit or PDGFRA receptor. While highly effective, tyrosine …

Targeted therapy with a tyrosine kinase inhibitor (TKI) such as imatinib is effective in treating
gastrointestinal stromal tumor (GIST), but it is rarely curative. Despite the presence of a …